Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
KEYNOTE-042 研究中，帕博利珠单抗与化疗作为一线治疗方案在非小细胞肺癌且程序性死亡配体-1 肿瘤比例评分≥1%的患者中的五年疗效
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.02885
de Castro, Gilberto Jr; Kudaba, Iveta; Wu, Yi-Long; Lopes, Gilberto; Kowalski, Dariusz M; Turna, Hande Z; Caglevic, Christian; Zhang, Li; Karaszewska, Boguslawa; Laktionov, Konstantin K; Srimuninnimit, Vichien; Bondarenko, Igor; Kubota, Kaoru; Mukherjee, Rinee; Lin, Jianxin; Souza, Fabricio; Mok, Tony S K; Cho, Byoung Chul
